摘要
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to overcome it remains an urgent clinical problem to be solved. Thus, a comprehensive and thorough understanding for mechanisms of drug resistance in mCRPC is indispensable to develop novel and better therapeutic strategies. In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Most importantly, in order to improve efficacy of these drugs, strategies of overcoming drug resistance are also discussed based on their mechanisms respectively.
学科与关键词
- Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?Chen, Ming-kun; Liang, Zhi-jian; Luo, Dao-Sheng; Xue, Kang-yi; Liao, De-ying; Li, Zheshen; Yu, Yuzhong; Chen, Zhe-Sheng*; Zhao, Shan-Chao*Frontiers in Pharmacology, 2022, 13: 843110.被引 4
- Abiraterone acetate: A novel drug for castration-resistant prostate carcinomaR, NandhaJournal of Postgraduate Medicine, 2012, 58(3): 203.
- Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glanceJian, Jingang; Wang, Xin'an; Zhang, Jun; Zhou, Chenchao; Hou, Xiaorui; Huang, Yuhua; Hou, Jianquan*; Lin, Yuxin*; Wei, Xuedong*Frontiers in Endocrinology, 2024, 15: 1360430.
